4Dar P, Sachs AS, Strassburger D. Ovarian function before and after salpingectomy in artificial reproductive technology [ J ]. Hum Reprod, 2000, 15(1) : 142 -144.
3Boivin J, Bunting L, Collins JA, et al. International estimates of infertility prevalence and treatment-seeking: potential need and demand for infertility medical care. Hum Reprod, 2007,22 : 1506- 1512.
4Gunby J, Bissonnette F, Libraeh C, et al. Assisted reproductive technologies(ART) in Canada: 2004 results from the Canadian ART Register. Fertil Steril, 2008,89 : 1123-1132.
5Serafini P, Batzofin J. Diagnosis of female infertility. A comprehensive approach. J Reprod Med, 1989, a4:29 - 40.
6Zeyneloglu HB, Arici A, Olive DL. Adverse effects of hydrosalpinx on pregnancy rates after in vitro fertilization - embryo transfer. Fertil Steril, 1998, 70: 492-499.
7Camus E, Poncelet C, Goffinet F, et al. Pregnancy rates after invitro fertilization in cases of tubal infertility with and without hydrosalpinx: a meta- analysis of published compara- tivestudies. Hum Reprod, 1999, 14: 1243-1249.
8Hammad IEHN, Afnan M, Evans J, et al. A postal survey of hydrosalpinx management prior to IVF in the United Kingdom. Hum Rep rod, 2004, 19:1009 - 1012.
9Stewart CL, Kaspar P, BrunetL J, et al. Blastocyst Implantation depend sonmaternal expression of leukemia inhibitory factor. Nature, 1992, 359:76-79.
10Emre S, Umit AK, Hakan C, et al. Removal of hydrosalpinges increases endometrial leukemia inhibitory factor (LIF) expression at the time of the implantation window. Hum Reprod, 2005, 20: 3012-3017.
